Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of [177Lu]Lu-FF58 in advanced solid tumors
NL-OMON59312Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 FF58 in glioblastoma (GBM), pancreatic adenocarcinoma (PDAC) and gastroesophageal junction adenocarcinoma, sponsored by Novartis. Primary endpoint: Primary endpoint(s). Started Dec 2023; status: completed.
02
Drugs
lutetium Lu 177 FF58
03
Conditions
glioblastoma (GBM)pancreatic adenocarcinoma (PDAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON59312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59312.